Northern Trust Corp Bio Atla, Inc. Transaction History

Northern Trust Corp

$572 Billion
Q1 2024

A detailed history of Northern Trust Corp transactions in Bio Atla, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 353,940 shares of BCAB stock, worth $484,897. This represents 0.0% of its overall portfolio holdings.

Number of Shares

353,940

Previous 355,894 0.55%

Holding current value

$484,897

Previous $875,000 39.09%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$1.88 - $3.46 $3,673 - $6,760	-1,954 Reduced 0.55%	353,940 $1.22 Million
Q4 2023 Feb 13, 2024	SELL	$1.27 - $3.18 $1,861 - $4,661	-1,466 Reduced 0.41%	355,894 $875,000
Q3 2023 Nov 13, 2023	SELL	$1.7 - $3.07 $12,610 - $22,773	-7,418 Reduced 2.03%	357,360 $607,000
Q2 2023 Aug 11, 2023	BUY	$2.83 - $3.87 $776,486 - $1.06 Million	274,377 Added 303.51%	364,778 $1.09 Million
Q1 2023 May 15, 2023	BUY	$2.3 - $8.25 $11,541 - $41,398	5,018 Added 5.88%	90,401 $242,000

Q4 2022 Feb 13, 2023	BUY	$7.63 - $11.01 $103,218 - $148,943	13,528 Added 18.83%	85,383 $704,000
Q3 2022 Nov 14, 2022	BUY	$2.94 - $11.87 $53,131 - $214,514	18,072 Added 33.6%	71,855 $553,000
Q2 2022 Aug 12, 2022	SELL	$2.13 - $5.38 $256,213 - $647,149	-120,288 Reduced 69.1%	53,783 $153,000
Q1 2022 May 13, 2022	SELL	$4.38 - $18.78 $26,179 - $112,248	-5,977 Reduced 3.32%	174,071 $871,000
Q4 2021 Feb 08, 2022	BUY	$19.0 - $30.95 $73,112 - $119,095	3,848 Added 2.18%	180,048 $3.54 Million
Q3 2021 Nov 15, 2021	BUY	$29.44 - $43.74 $855,173 - $1.27 Million	29,048 Added 19.74%	176,200 $5.19 Million
Q2 2021 Aug 13, 2021	BUY	$38.07 - $56.17 $929,364 - $1.37 Million	24,412 Added 19.89%	147,152 $6.24 Million
Q1 2021 May 12, 2021	BUY	$32.41 - $70.91 $3.98 Million - $8.7 Million	122,740 New	122,740 $6.24 Million

Others Institutions Holding BCAB

# of Institutions

Shares Held

24.8M

Call Options Held

140K

Put Options Held

4.6K

View Full List

About BioAtla, Inc.

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $49.7M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

More about BCAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Bio Atla, Inc. Transaction History